Pediatrix Medical Group, Inc. (MD) /
The cash flow of Pediatrix Medical Group, Inc. over the past 10 years
Chart Pediatrix Medical Group, Inc.: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, Pediatrix Medical Group, Inc.'s operating cash flow was $271.09M and its capital expenditures $18.46M, leaving free cash flow of $252.63M. Free cash flow was above zero in all 10 years shown. It ranged from $44.49M in fiscal 2021 to $485.23M in fiscal 2017. Capital expenditures were highest in fiscal 2016, at $39.26M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $271.09M | $18.46M | $252.63M |
| 2024ended Dec 31, 2024 | $206.57M | $22.02M | $184.55M |
| 2023ended Dec 31, 2023 | $137.32M | $33.33M | $104M |
| 2022ended Dec 31, 2022 | $166.94M | $29.71M | $137.23M |
| 2021ended Dec 31, 2021 | $76.74M | $32.25M | $44.49M |
| 2020ended Dec 31, 2020 | $204.62M | $28.79M | $175.83M |
| 2019ended Dec 31, 2019 | $357.71M | $19.27M | $338.44M |
| 2018ended Dec 31, 2018 | $313.71M | $17.12M | $296.59M |
| 2017ended Dec 31, 2017 | $511.38M | $26.15M | $485.23M |
| 2016ended Dec 31, 2016 | $443.78M | $39.26M | $404.51M |
Fiscal years as Pediatrix Medical Group, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Pediatrix Medical Group, Inc.
- The revenue of Pediatrix Medical Group, Inc.
- The profitability of Pediatrix Medical Group, Inc.
- The debt of Pediatrix Medical Group, Inc.
- All of Pediatrix Medical Group, Inc.'s financials, charted
Companies of a similar size
- PAYOPayoneer Global Inc.
- PRCHPorch Group, Inc.
- ECPGENCORE CAPITAL GROUP, INC.
- TALOTalos Energy Inc.
- FSLYFASTLY, INC.
Not investment advice. This page shows what Pediatrix Medical Group, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.